- Home
- HAFN vs SUPN Comparison
HAFN vs SUPN Comparison
Compare HAFN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | SUPN |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HAFN | SUPN |
|---|---|---|
| Price | $6.10 | $48.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.3M | 679.9K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,221,808,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.16 |
| Revenue Next Year | $0.30 | $23.82 |
| P/E Ratio | $10.07 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $3.61 | $29.16 |
| 52 Week High | $6.64 | $57.65 |
Technical Indicators
Market Signals| Indicator | HAFN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 42.50 |
| Support Level | $5.63 | $48.02 |
| Resistance Level | $6.25 | $50.09 |
| Average True Range (ATR) | 0.13 | 1.46 |
| MACD | 0.05 | -0.30 |
| Stochastic Oscillator | 76.42 | 10.11 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.